List of Excipients in Branded Drug DUAKLIR PRESSAIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	DUAKLIR PRESSAIR	aclidinium bromide and formoterol fumarate	0310-0900	LACTOSE MONOHYDRATE	2029-03-13
Covis Pharma US Inc	DUAKLIR PRESSAIR	aclidinium bromide and formoterol fumarate	70515-001	LACTOSE MONOHYDRATE	2029-03-13
Circassia Pharmaceuticals Inc	DUAKLIR PRESSAIR	aclidinium bromide and formoterol fumarte	72124-001	LACTOSE MONOHYDRATE	2029-03-13

Duaklir Pressair Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Duaklir Pressair is a fixed-dose dry-powder inhaler combining aclidinium bromide, a long-acting muscarinic antagonist, with formoterol fumarate, a long-acting beta2-adrenergic agonist. Its commercial platform is built around a lactose-based inhalation powder and the Pressair multidose inhaler. The primary excipient opportunity is not a conventional reformulation of the active ingredients. It is the development of carrier-engineered powders, lactose alternatives, device-compatible blends, and differentiated presentations that improve dose consistency, moisture resistance, usability, and geographic manufacturability.

The product has limited excipient complexity. That simplifies manufacturing but narrows the number of conventional formulation differentiators. Commercial value is concentrated in inhalation performance, device engineering, lifecycle management, and regulatory positioning.

What excipients are used in Duaklir Pressair?

Duaklir Pressair uses lactose monohydrate as the principal inactive ingredient in its dry-powder formulation. The product does not use a propellant, aqueous solvent, preservative, or capsule shell. The Pressair inhaler meters the powder from a multidose reservoir and delivers it through patient inhalation.

Product attribute	Duaklir Pressair
Active ingredients	Aclidinium bromide and formoterol fumarate
Dosage form	Dry powder for oral inhalation
Strength	400 mcg aclidinium bromide and 12 mcg formoterol fumarate per actuation
Delivered active dose	Approximately 343 mcg aclidinium and 11.5 mcg formoterol
Primary excipient	Lactose monohydrate
Delivery device	Pressair multidose dry-powder inhaler
Propellant	None
Preservative	None identified in the U.S. prescribing information
Indication	Maintenance treatment of airflow obstruction in COPD
U.S. NDA	NDA 207930

The U.S. label identifies lactose monohydrate as the inactive ingredient. The European product information also identifies lactose and warns that the product contains a small amount of milk proteins, which is relevant to patients with severe milk-protein allergy. [1,2]

Why lactose is commercially important

In a carrier-based dry-powder inhaler, lactose is more than a bulking agent. Its particle-size distribution, surface morphology, crystallinity, moisture content, and fine-particle fraction affect:

• Adhesion of micronized drug particles to carrier particles.
• Detachment of active particles during inhalation.
• Delivered-dose uniformity.
• Fine-particle dose and lung deposition.
• Powder flow through the inhaler.
• Stability under humidity and temperature stress.
• Dose reproducibility over the inhaler’s life.

Duaklir’s two active ingredients have different physicochemical properties and different target dose levels. A single lactose carrier system must support both aclidinium bromide and formoterol fumarate without compromising blend uniformity or aerosolization.

How does the Duaklir Pressair excipient system work?

The commercial formulation strategy is likely based on micronized active pharmaceutical ingredients blended with inhalation-grade lactose. The lactose provides bulk, improves powder handling, and acts as a carrier for the low-dose active particles. During inhalation, airflow through the Pressair device separates a portion of the active particles from the carrier and transports the respirable fraction into the lower airways.

The key formulation variables are:

1. Lactose particle-size distribution.
2. Active-particle size and morphology.
3. Blend order and shear exposure.
4. Surface energy and adhesion forces.
5. Moisture uptake.
6. Device resistance and airflow design.
7. Powder retention within the metering system.
8. Dose uniformity at the beginning, middle, and end of device life.

A formulation that produces acceptable assay values in bulk may still fail on emitted dose, fine-particle dose, or content uniformity after storage. That creates a technical barrier for generic and follow-on manufacturers.

What performance attributes matter most?

For Duaklir-type products, the most commercially relevant critical quality attributes are:

Attribute	Commercial effect
Delivered-dose uniformity	Determines label compliance and regulatory acceptance
Fine-particle dose	Affects lung deposition and clinical comparability
Aerodynamic particle-size distribution	Supports equivalence and performance claims
Moisture stability	Controls aggregation and dose drift
Blend uniformity	Important because aclidinium and formoterol are present at different masses
Device emptying	Reduces residual drug and supports labeled actuation count
Powder flow	Enables consistent metering and manufacturing throughput
Extractables and leachables	Relevant to device-material qualification

What excipient strategies could create commercial opportunities for Duaklir?

The strongest opportunities are carrier engineering, lactose substitution, humidity protection, and device-compatible lifecycle products.

Engineered lactose carriers

An inhalation supplier could develop lactose with controlled:

• Fine-particle content.
• Surface roughness.
• Crystallinity.
• Moisture content.
• Specific surface area.
• Particle-size distribution.

A tailored lactose grade could improve fine-particle dose or reduce variability without changing the active ingredients. Such a platform could support a differentiated generic, an authorized generic, or a contract-manufacturing arrangement.

The commercial barrier is that the excipient change must be linked to measurable product performance. A new lactose grade alone is unlikely to justify premium pricing unless it improves stability, device yield, bioequivalence probability, or manufacturing cost.

Lactose-free formulations

A lactose-free Duaklir equivalent could target patients with milk-protein sensitivity and markets where lactose-free inhalation products have commercial value. Candidate carriers include mannitol, trehalose, and other inhalation-grade polyols or crystalline materials.

The technical risks are substantial:

• Different surface energy compared with lactose.
• Altered drug adhesion and detachment.
• Higher or lower moisture sensitivity.
• Potential changes in powder electrostatics.
• Different flow behavior in the Pressair metering system.
• Need for new toxicological and inhalation safety support.
• Possible loss of in vitro equivalence to the reference product.

A lactose-free product could be positioned as a differentiated inhaler rather than a simple generic. That may support a 505(b)(2)-type strategy in the United States if the proposed product does not fit the conventional abbreviated pathway, although the regulatory route depends on the exact formulation, device, and clinical claims.

Moisture-control excipients and packaging

Humidity is a major failure mode for carrier-based dry powders. Moisture can increase cohesion, promote agglomeration, alter lactose surfaces, and reduce respirable dose. Opportunities include:

• Improved desiccant systems.
• High-barrier blister or reservoir packaging.
• Moisture-scavenging device components.
• Excipient grades with lower water activity.
• Surface-modified carrier particles.
• Secondary packaging designed for tropical climates.

The most commercially attractive solution may be packaging rather than a new excipient. Packaging changes can preserve the existing formulation while improving shelf life and distribution in high-humidity markets.

Force-control agents

Small quantities of magnesium stearate, leucine, or related surface-active materials are used in some dry-powder platforms to modify adhesion and aerosolization. Such materials could improve dose release from lactose or reduce humidity-induced cohesion.

For Duaklir, force-control agents would create a materially different formulation. The sponsor would need to establish:

• Inhalation safety.
• Uniform distribution.
• Long-term stability.
• Device compatibility.
• Absence of adverse effects on active degradation.
• Comparable delivered dose and aerodynamic performance.

This approach has greater differentiation potential than simply changing lactose grade, but it also creates a larger regulatory and intellectual-property burden.

What formulations are protected by Duaklir-related intellectual property?

The potentially relevant IP categories are broader than the named excipient. They include:

• Fixed-dose aclidinium/formoterol combinations.
• Dry-powder formulations containing both actives.
• Particle-size specifications.
• Lactose carrier systems.
• Powder blending processes.
• Metering systems.
• Multidose Pressair device architecture.
• Dose counters and inhalation-actuated mechanisms.
• Manufacturing processes for micronized active ingredients.
• Stability and packaging configurations.

The product’s protection should be analyzed by separating formulation patents from device patents. A competitor may avoid a formulation claim while remaining exposed to device claims, or use a non-Pressair device while facing equivalence requirements for the powder.

A public product label confirms the approved formulation and device but does not establish the complete patent estate. Patent scope, ownership, terminal disclaimers, Orange Book listings, and expiration dates require claim-level review of the relevant U.S., European, and national patent records. The core commercial issue is whether a follow-on product can use the same active combination with a different excipient system and different inhaler while still satisfying FDA equivalence requirements.

What is the FDA regulatory status of Duaklir Pressair?

FDA approved Duaklir Pressair for the twice-daily maintenance treatment of airflow obstruction in patients with COPD. The product is a small-molecule combination inhalation drug, not a biologic. Biosimilar rules therefore do not apply. A competing product would generally be evaluated through an ANDA if it can meet the applicable pharmaceutical-equivalence, bioequivalence, device, and labeling requirements. A materially different formulation or device may require a different regulatory pathway.

The product’s regulatory risk is concentrated in combination-product equivalence. A follow-on manufacturer must address more than active-ingredient identity. The device and formulation jointly determine:

• Emitted dose.
• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Inspiratory-flow dependence.
• Device resistance.
• Priming and actuation behavior.
• Patient-use performance.

FDA’s product-specific requirements for orally inhaled products can make development more expensive than a conventional tablet ANDA. [3]

What is the Orange Book status of Duaklir Pressair?

Duaklir Pressair is associated with U.S. NDA 207930. Orange Book analysis should distinguish:

• Listed drug status.
• Patent listings for the drug substance or product.
• Method-of-use listings.
• Device-related protection.
• Pediatric exclusivity.
• Any regulatory exclusivity that has expired.

The original U.S. approval occurred in 2015, so any original new-drug exclusivity period is no longer the primary barrier. Current entry risk depends on surviving patents, patent-term adjustments, approved indications, and the ability of an ANDA applicant to demonstrate equivalence using a non-Pressair device.

When does Duaklir Pressair lose exclusivity?

The product’s commercial exclusivity is not determined by a single date. It depends on separate periods for FDA regulatory exclusivity, active-ingredient or combination patents, formulation patents, method-of-use patents, and device patents.

Protection category	Relevance to Duaklir
New chemical entity exclusivity	Not the principal current barrier because the product was approved in 2015
Combination-product patents	May cover aclidinium/formoterol formulations or use
Formulation patents	May cover carrier systems, particle properties, or blend composition
Device patents	May cover Pressair metering, dose counting, or airflow mechanisms
Method-of-use patents	May cover COPD maintenance treatment or dosing regimens
Manufacturing patents	May cover micronization, blending, or powder processing
Regulatory exclusivity	May have expired or be limited relative to patent protection

A Paragraph IV challenger could target listed patents before expiration by asserting invalidity, unenforceability, or non-infringement. The economic value of the challenge would depend on the size of the U.S. COPD market, the number of competing long-acting bronchodilator combinations, and the applicant’s ability to obtain approval for its own device.

Which companies are competing with Duaklir Pressair?

Duaklir competes in the long-acting muscarinic antagonist/long-acting beta2 agonist, or LAMA/LABA, COPD market.

Product	Active ingredients	Delivery platform	Strategic relevance
Duaklir Pressair	Aclidinium/formoterol	Dry powder inhaler	Twice-daily LAMA/LABA
Anoro Ellipta	Umeclidinium/vilanterol	Dry powder inhaler	Once-daily LAMA/LABA
Bevespi Aerosphere	Glycopyrrolate/formoterol	Metered-dose inhaler	Pressurized aerosol platform
Stiolto Respimat	Tiotropium/olodaterol	Soft-mist inhaler	Once-daily soft-mist delivery
Utibron Neohaler	Glycopyrrolate/indacaterol	Dry powder inhaler	Competing DPI combination

The main commercial disadvantage for Duaklir is twice-daily dosing in a market where once-daily products have strong adherence and formulary positioning. The main technical advantage is the established Pressair powder platform, which can support lifecycle products if the device and formulation are improved without disrupting patient familiarity.

What generic entry risks exist for Duaklir Pressair?

Generic entry risk is moderate to high over the long term but technically more complex than for an oral fixed-dose combination. The principal risks for an entrant are:

1. Matching the reference product’s aerodynamic performance.
2. Demonstrating dose uniformity across the full device life.
3. Developing a substitute device acceptable to FDA.
4. Proving performance across patient-relevant inhalation flows.
5. Avoiding formulation and device patent claims.
6. Controlling lactose grade and active-particle variability.
7. Establishing manufacturing scale without blend segregation.
8. Meeting combination-product quality requirements.

A generic using the same lactose strategy may reduce formulation risk but increase patent exposure. A lactose-free or force-controlled formulation may reduce patent overlap but increase regulatory and development risk.

What licensing and manufacturing opportunities exist?

The most practical licensing opportunities are likely to arise in four areas:

Excipient platform licensing

An inhalation-excipient supplier could license a controlled-particle lactose, lactose-free carrier, or force-control technology to a generic manufacturer. The deal structure could include an upfront payment, development milestones, and royalties linked to commercial sales.

Device and formulation co-development

Device manufacturers can partner with regional pharmaceutical companies to create a Duaklir-equivalent product using a proprietary multidose inhaler. The value proposition is strongest in markets where the Pressair device is not widely available or where local manufacturing is required.

Contract manufacturing

Specialized inhalation manufacturers can offer:

• Micronization.
• Carrier blending.
• Device filling.
• Inhaler assembly.
• Dose-uniformity testing.
• Aerodynamic particle-size testing.
• Stability packaging.

The manufacturing barrier is higher than for standard oral solids because small changes in humidity, shear, equipment geometry, or active-particle size can affect performance.

Regional lifecycle products

A lactose-free or humidity-stable product could be developed for markets with high prevalence of milk-protein allergy, high ambient humidity, or limited cold-chain and pharmaceutical storage infrastructure. The opportunity is more credible when tied to a specific device and packaging advantage.

How strong is the Duaklir Pressair patent estate?

The estate’s practical strength depends on claim coverage across three layers:

1. The aclidinium/formoterol combination.
2. The inhalation powder and carrier system.
3. The Pressair device.

Combination claims can be vulnerable if prior art discloses both active classes or similar COPD combinations. Formulation claims are stronger when they specify measurable particle, aerosol, or stability parameters that are difficult to design around. Device claims can be commercially important because a generic may need to reproduce the functional behavior of the reference inhaler even if it uses a different physical design.

The most defensible lifecycle strategy would combine formulation claims with device and manufacturing claims. A single lactose-composition claim would provide narrower protection and may be easier to avoid through carrier substitution.

Key Takeaways

• Duaklir Pressair uses a lactose-monohydrate dry-powder formulation with aclidinium bromide and formoterol fumarate.
• The highest-value excipient opportunities involve carrier engineering, moisture control, lactose substitution, and force-control technology.
• A lactose-free version could create commercial differentiation but would likely carry greater regulatory and equivalence risk.
• Generic entry is more difficult than for oral products because formulation and device performance are interdependent.
• Duaklir competes with once-daily LAMA/LABA products, including Anoro Ellipta and Stiolto Respimat.
• The relevant IP categories include combination, formulation, device, method-of-use, and manufacturing patents.
• The original 2015 FDA approval means current market protection depends primarily on surviving patent and device barriers rather than original regulatory exclusivity.
• The best licensing targets are inhalation-excipient suppliers, multidose inhaler developers, and contract manufacturers with aerosol-performance capabilities.

FAQs

Can lactose monohydrate be replaced in a Duaklir generic?

Yes, but replacing lactose would create a materially different inhalation formulation. The developer would need to establish inhalation safety, stability, dose uniformity, aerodynamic equivalence, and device compatibility.

Is Duaklir Pressair a biologic product eligible for biosimilar competition?

No. Duaklir is a small-molecule combination drug. Competition would generally involve generic or follow-on inhalation pathways rather than biosimilar regulation.

Could a generic use a different inhaler from Pressair?

Potentially. A different device would need to demonstrate acceptable performance and regulatory equivalence or support an alternative regulatory pathway. Device differences can affect dose delivery, airflow resistance, and patient handling.

What is the most attractive excipient opportunity for Duaklir?

A controlled-particle lactose or moisture-resistant carrier system is the lowest-risk opportunity because it preserves the basic platform. A lactose-free formulation has greater differentiation potential but also greater development and regulatory risk.

Does a new excipient automatically create patent protection?

No. Patentability depends on the specific composition, particle attributes, process, performance benefit, and claim scope. A new excipient grade may be protected through composition, use, process, or formulation claims, but the claims must distinguish the prior art.

References

1. U.S. Food and Drug Administration. (2023). Duaklir Pressair prescribing information, NDA 207930.

2. European Medicines Agency. (2023). Duaklir Genuair: EPAR product information.

3. U.S. Food and Drug Administration. (2020). Draft guidance for industry: Metered dose inhaler and dry powder inhaler drug products: Chemistry, manufacturing, and controls documentation.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease.